市场调查报告书
商品编码
1532134
胎儿监护市场:依产品、携带性、方法、应用、最终用户、地区、机会、预测,2017-2031Fetal Monitoring Market Assessment, By Product, By Portability, By Method, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
2024-2031年预测期间,全球胎儿监护市场规模预计将以7.02%的年复合成长率扩大,从2023年的45.4亿美元成长到2031年的78.1亿美元。出生率上升、妊娠相关併发症的流行以及技术进步等因素推动全球胎儿监测市场的发展。
胎儿监视器是用于评估怀孕期间胎儿健康状况的重要工具。这些设备包括超音波系统、电子胎儿监视器和胎儿多普勒仪,可帮助医疗保健提供者监测胎儿心率、胎动和母体宫缩。这一成长是由多种因素推动的,包括早产和妊娠相关併发症发生率上升、技术进步以及孕产妇护理意识的提高。然而,高成本、监管障碍以及准妈妈和医疗保健提供者意识有限等挑战可能会阻碍市场扩张。虽然北美目前占据最大的市场占有率,但在医疗保健基础设施改善和对先进监控解决方案的需求不断成长的推动下,亚太地区预计将呈现最高的成长率。
2024年 6月 26 日,美国食品药物管理局(FDA)授予 Clarius Health Corp 以人工智慧为基础的手持式超音波设备的 510(k)许可。 Clarius OB AI 经过 30,000 多张胎儿超音波影像的训练,可自动正确放置卡尺来计算胎儿生物特征测量值,使用者可以透过 Clarius 应用程式将测量值传输到患者的电子健康记录中。
妊娠相关併发症的日益普及是胎儿监测设备需求的主要驱动力。妊娠糖尿病、高血压和早产等疾病变得越来越普遍,需要加强监测以确保母亲和胎儿的健康和安全。由于这些併发症可能会导致严重的健康风险,因此医疗保健提供者越来越依赖胎儿监测系统来促进及时干预并有效管理高风险怀孕。技术的进步实现更准确、更有效率的监控解决方案,而这些设备的市场预计将会成长。孕妇对产前护理重要性的认识不断提高,以及现代胎儿监测技术不断评估胎儿和孕产妇健康的能力,推动了需求的激增。怀孕期间的问题,例如妊娠糖尿病和子痫前症,甚至在出生后几十年也会增加死亡率。怀孕期间出现严重问题的女性过早死亡的风险较高。这种流行导致了全球胎儿监测市场的成长。
本报告调查了全球胎儿监护市场,包括市场概述以及依产品、携带性、方法、应用、最终用户、地区趋势和进入市场的公司概况。
Global fetal monitoring market is projected to witness a CAGR of 7.02% during the forecast period 2024-2031, growing from USD 4.54 billion in 2023 to USD 7.81 billion in 2031. Factors are driving the global fetal monitoring market such as increasing birth rates, prevalence of pregnancy related complications, and technological advancements.
Fetal monitoring devices are essential tools used to assess the health and well-being of a fetus during pregnancy. These devices include ultrasound systems, electronic fetal monitors, and fetal dopplers, which help healthcare providers to monitor fetal heart rates, movements, and maternal contractions. This growth is driven by several factors, including the rising incidence of preterm births and pregnancy-related complications, advancements in technology, and increasing awareness of prenatal care. However, challenges such as high costs, regulatory hurdles, and limited awareness among expectant mothers and healthcare providers may hinder market expansion. North America currently holds the largest market share, but Asia-Pacific is expected to exhibit the highest growth rate, influenced by improvements in healthcare infrastructure and rising demand for advanced monitoring solutions.
On 26th June 2024, the food and drug administration (FDA) granted 510(k) approval to Clarius Health Corp for its AI-based handheld ultrasound device. Clarius OB AI, has been trained on over 30,000 fetal ultrasound images, automates appropriate caliper placement for calculating fetal biometry measurements and allows users to add the measurements to patient electronic medical records via the Clarius app.
Increasing Prevalence of Pregnancy Related Complications
The increasing prevalence of pregnancy-related complications is significantly driving the demand for fetal monitoring devices. Conditions such as gestational diabetes, hypertension, and preterm labor have become more common, necessitating enhanced monitoring to ensure the health and safety of both the mother and fetus. As these complications can lead to serious health risks, healthcare providers are increasingly relying on fetal monitoring systems to facilitate timely interventions and manage high-risk pregnancies effectively. The market for these devices is projected to grow, with advancements in technology allowing for more accurate and efficient monitoring solutions. The surge in demand is fueled by rising awareness among expectant mothers about the importance of prenatal care and the capabilities of modern fetal monitoring technologies, which enable continuous assessment of fetal well-being and maternal health. Pregnancy problems, such as gestational diabetes or preeclampsia, may increase the chance of mortality even decades after delivery. Women who had serious problems during pregnancy have a higher risk of premature mortality. Such prevalence leads to growth of the global fetal monitoring market.
Technological Advancements to Drive Market Growth
Technological advancements in fetal monitoring are revolutionizing prenatal care, enhancing both the accuracy and convenience of monitoring fetal health. Innovations such as wearable devices, such as the abdominal patch developed by UC Irvine engineers in November 2022, allows expectant mothers to track fetal heart rates at home using a smartphone, promoting continuous monitoring without the need for trained technicians. The device utilizes an algorithm called Lullaby, which effectively isolates fetal electrocardiogram signals from maternal heartbeats, improving the clarity of data collected. Additionally, transabdominal fetal monitors are gaining traction, offering a non-invasive method that simplifies the monitoring process by using adhesive patches that do not require constant adjustments. These advancements improve the user experience and address challenges related to the global shortage of skilled healthcare professionals.
Portable Ultrasound Devices to Grow at a Fast Rate
Portable ultrasound devices are expected to see a significant increase in demand for fetal monitoring in the coming years due to several key factors. Handheld ultrasound systems are compact, lightweight, and easy for healthcare providers to use at the point-of-care, allowing for more frequent monitoring of fetal health. This is especially beneficial for high-risk pregnancies or in remote areas with limited access to traditional ultrasound machines. Technological advancements are enabling portable ultrasound devices to produce higher quality images comparable to cart-based systems. As the gap in functionality continues to decline, portable ultrasound will become an increasingly viable option for fetal monitoring. Artificial intelligence is being integrated with portable ultrasound to enhance diagnostic capabilities and guide treatment decisions, especially in emergency situations.
Konica Minolta Healthcare Americas, Inc. launched PocketPro H2, a wireless portable ultrasound device for general imaging in point-of-care applications, in July 2023. Konica Minolta Healthcare Americas Inc. partnered with Healcerion Co Ltd to commercialize the PocketPro H2 in the United States for urology and gynecology applications, bringing a new level of flexibility and affordability to ultrasound.
Hospitals to Dominate the Global Fetal Monitoring Market Share
Hospitals are equipped with advanced ultrasound technology and have specialists trained in interpreting fetal ultrasound images. They can provide comprehensive fetal monitoring throughout pregnancy, from early dating scans to detailed anatomy surveys and growth assessments. Hospitals have the capability to perform more specialized ultrasound exams such as fetal echocardiograms to evaluate the fetal heart. Additionally, hospitals are equipped to handle high-risk pregnancies that require closer monitoring, such as those with maternal conditions such as diabetes or preeclampsia, or fetal abnormalities detected in ultrasound. Portable ultrasound devices are increasingly being used in hospitals to provide point-of-care monitoring, allowing for more frequent checks on fetal well-being.
Future Market Scenario (2024-2031F)
Noninvasive fetal electrocardiography (ECG) and uterine contraction monitoring technologies are expected to bring novel metrics and potentially improved safety to obstetrics in coming years. These technologies filter ambient noise and focus on the fetal ECG waveform and uterine contraction patterns to provide more accurate monitoring. Fetal monitoring bands with innovative features like real-time data analysis, wireless connectivity, and portability are being introduced to make monitoring more convenient for providers and expectant mothers. These wearable devices allow for ambulatory monitoring outside the hospital setting.
Key Players Landscape and Outlook
The market witnessed some substantial market deals such as acquisitions, regulatory approvals, and product launches to expand the market share of key players. NeuroLogica Corp. launched the V6, their latest ultrasound system, in November 2023. The V6 provides full imaging capabilities in 2D, 3D, and color picture quality, with a focus on Women's Health and Urology. The V6 recently gained 510(k) clearance from the United States Food and Drug Administration for commercial usage, and it is intended to be cost-effective while meeting workflow and productivity requirements. A semi-automated tool based on deep learning that allows for one-click fetal growth measures, improving exam uniformity while minimizing keystrokes and allowing clinicians to focus more on patient care.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.